Overview Dividends

(DHR) Danaher - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2358511028

Bioprocessing, Diagnostics, Instruments, Consumables, Services

DHR EPS (Earnings per Share)

EPS Growth (3Y CAGR): -12.02%
EPS Trend (3Y Correlation): -78.3%

DHR Revenue

Revenue Growth (3Y CAGR): -8.87%
Revenue Trend (3Y Correlation): -62.2%

Description: DHR Danaher

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, research, and industrial products across three operating segments-Biotechnology, Life Sciences, and Diagnostics-serving customers in the United States, China, and other global markets.

In FY 2023 the company generated ≈ $25.5 billion in revenue, with an operating margin of ≈ 20 % and free cash flow of $5.4 billion, reflecting the high-margin nature of its instrument and consumables businesses; however, the exact forward-look depends on the pace of integration of recent acquisitions such as Cytiva and the continuation of its “Danaher Business System” productivity improvements.

Key macro drivers include the aging global population, rising prevalence of chronic diseases, and sustained investment in personalized medicine, all of which boost demand for bioprocessing equipment, genomics tools, and point-of-care diagnostics-segments where Danaher holds leading market positions. A potential headwind is the cyclical nature of capital-intensive hospital spending, which can be amplified by macro-economic uncertainty or changes in reimbursement policies.

For a deeper, data-driven valuation framework, the ValueRay platform provides granular metrics that can complement your analysis.

DHR Stock Overview

Market Cap in USD	144,972m
Sub-Industry	Health Care Equipment
IPO / Inception	1979-01-05

DHR Stock Ratings

Growth Rating	-29.5%
Fundamental	49.2%
Dividend Rating	63.2%
Return 12m vs S&P 500	-31.1%
Analyst Rating	4.62 of 5

DHR Dividends

Dividend Yield 12m	0.58%
Yield on Cost 5y	0.63%
Annual Growth 5y	14.06%
Payout Consistency	94.7%
Payout Ratio	21.0%

DHR Growth Ratios

Growth Correlation 3m	6.1%
Growth Correlation 12m	-68.2%
Growth Correlation 5y	-10.3%
CAGR 5y	-0.23%
CAGR/Max DD 3y (Calmar Ratio)	-0.01
CAGR/Mean DD 3y (Pain Ratio)	-0.02
Sharpe Ratio 12m	-0.17
Alpha	-34.27
Beta	0.802
Volatility	23.78%
Current Volume	5818.1k
Average Volume 20d	4008.7k
Stop Loss	204.5 (-3%)
Signal	1.12

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (3.41b TTM) > 0 and > 6% of Revenue (6% = 1.44b TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -0.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 17.52% (prev 12.34%; Δ 5.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 6.17b > Net Income 3.41b (YES >=105%, WARN >=100%)

Net Debt (15.60b) to EBITDA (6.75b) ratio: 2.31 <= 3.0 (WARN <= 3.5)

Current Ratio 1.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (719.1m) change vs 12m ago -3.14% (target <= -2.0% for YES)

Gross Margin 61.52% (prev 59.27%; Δ 2.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 29.98% (prev 30.00%; Δ -0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 15.01 (EBITDA TTM 6.75b / Interest Expense TTM 291.0m) >= 6 (WARN >= 3)

Altman Z'' 4.11

(A) 0.05 = (Total Current Assets 11.00b - Total Current Liabilities 6.79b) / Total Assets 81.62b

(B) 0.55 = Retained Earnings (Balance) 45.24b / Total Assets 81.62b

(D) 1.53 = Book Value of Equity 44.68b / Total Liabilities 29.28b

Total Rating: 4.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 49.22

1. Piotroski 7.0pt = 2.0

2. FCF Yield 3.03% = 1.51

3. FCF Margin 20.25% = 5.06

4. Debt/Equity 0.35 = 2.44

5. Debt/Ebitda 2.31 = -0.60

6. ROIC - WACC (= -2.54)% = -3.17

7. RoE 6.69% = 0.56

8. Rev. Trend -62.18% = -4.66

9. EPS Trend -78.28% = -3.91

What is the price of DHR shares?

As of October 17, 2025, the stock is trading at USD 210.92 with a total of 5,818,109 shares traded.
Over the past week, the price has changed by +3.15%, over one month by +10.93%, over three months by +9.31% and over the past year by -20.83%.

Is Danaher a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Danaher (NYSE:DHR) is currently (October 2025) a stock to sell. It has a ValueRay Fundamental Rating of 49.22 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DHR is around 185.86 USD . This means that DHR is currently overvalued and has a potential downside of -11.88%.

Is DHR a buy, sell or hold?

Danaher has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy DHR.

Strong Buy: 19
Buy: 4
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DHR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	243.2	15.3%
Analysts Target Price	243.2	15.3%
ValueRay Target Price	206.3	-2.2%

Last update: 2025-10-14 02:27

DHR Fundamental Data Overview

Market Cap USD = 144.97b (144.97b USD * 1.0 USD.USD)
P/E Trailing = 42.8941
P/E Forward = 24.3902
P/S = 6.0372
P/B = 2.8778
P/EG = 1.8485
Beta = 0.802
Revenue TTM = 24.01b USD
EBIT TTM = 4.37b USD
EBITDA TTM = 6.75b USD
Long Term Debt = 16.85b USD (from longTermDebt, last quarter)
Short Term Debt = 1.70b USD (from shortTermDebt, last quarter)
Debt = 18.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.60b USD (from netDebt column, last quarter)
Enterprise Value = 160.57b USD (144.97b + Debt 18.55b - CCE 2.96b)
Interest Coverage Ratio = 15.01 (Ebit TTM 4.37b / Interest Expense TTM 291.0m)
FCF Yield = 3.03% (FCF TTM 4.86b / Enterprise Value 160.57b)
FCF Margin = 20.25% (FCF TTM 4.86b / Revenue TTM 24.01b)
Net Margin = 14.21% (Net Income TTM 3.41b / Revenue TTM 24.01b)
Gross Margin = 61.52% ((Revenue TTM 24.01b - Cost of Revenue TTM 9.24b) / Revenue TTM)
Gross Margin QoQ = 66.63% (prev 61.42%)
Tobins Q-Ratio = 1.97 (Enterprise Value 160.57b / Total Assets 81.62b)
Interest Expense / Debt = 0.38% (Interest Expense 71.0m / Debt 18.55b)
Taxrate = 15.27% (100.0m / 655.0m)
NOPAT = 3.70b (EBIT 4.37b * (1 - 15.27%))
Current Ratio = 1.62 (Total Current Assets 11.00b / Total Current Liabilities 6.79b)
Debt / Equity = 0.35 (Debt 18.55b / totalStockholderEquity, last quarter 52.33b)
Debt / EBITDA = 2.31 (Net Debt 15.60b / EBITDA 6.75b)
Debt / FCF = 3.21 (Net Debt 15.60b / FCF TTM 4.86b)
Total Stockholder Equity = 51.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.18% (Net Income 3.41b / Total Assets 81.62b)
RoE = 6.69% (Net Income TTM 3.41b / Total Stockholder Equity 51.01b)
RoCE = 6.44% (EBIT 4.37b / Capital Employed (Equity 51.01b + L.T.Debt 16.85b))
RoIC = 5.45% (NOPAT 3.70b / Invested Capital 67.85b)
WACC = 7.99% (E(144.97b)/V(163.53b) * Re(8.97%) + D(18.55b)/V(163.53b) * Rd(0.38%) * (1-Tc(0.15)))
Discount Rate = 8.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.83%
[DCF Debug] Terminal Value 74.11% ; FCFE base≈4.96b ; Y1≈4.71b ; Y5≈4.51b
Fair Price DCF = 95.37 (DCF Value 68.29b / Shares Outstanding 716.1m; 5y FCF grow -6.55% → 3.0% )
EPS Correlation: -78.28 | EPS CAGR: -12.02% | SUE: 1.82 | # QB: 2
Revenue Correlation: -62.18 | Revenue CAGR: -8.87% | SUE: 0.18 | # QB: 0

Additional Sources for DHR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle